Roche
CARsgen to Study CLDN18.2 Drug, Roche's Tecentriq for Gastric Cancer Patients in China
China's NMPA cleared the firm's IND to study AB011 plus Tecentriq as first-line treatment for advanced CLDN18.2-positive gastric or gastroesophageal junction cancers.
In Brief This Week: Fusion Pharmaceuticals, Mainz Biomed, FDA, Medial EarlySign
News items for the week of May 1, 2023.
Sales from Roche's oncology portfolio grew 4 percent, bolstered by uptake of personalized medicine products Tecentriq and Perjeta.
Foundation Medicine Lays off 135 Employees
According to LinkedIn, the company has around 1,900 employees, making the cuts approximately 7 percent of the company's workforce.
Advanced Cancer Outcomes Predicted Using Model Based on Circulating Tumor DNA Metrics
Researchers developed a ctDNA-based machine learning model for predicting metastatic non-small cell lung cancer response to immunotherapy and related survival outcomes.
Feb 3, 2023
Oct 18, 2022